Efficacy of Immune Checkpoint Inhibitor

• Published in: Cancers 2023-07, Vol.15 (14)
• Main Authors: Nardin, Charlée, Hennemann, Aymeric, Diallo, Kadiatou, Funck-Brentano, Elisa, Puzenat, Eve, Heidelberger, Valentine, Jeudy, Géraldine, Samimi, Mahtab, Lesage, Candice, Boussemart, Lise, Peuvrel, Lucie, Rouanet, Jacques, Brunet-Possenti, Florence, Gerard, Emilie, Seris, Alice, Jouary, Thomas, Saint-Jean, Mélanie, Puyraveau, Marc, Saiag, Philippe, Aubin, François
• Format: Article
• Language: English
• Subjects: Analysis; Antibodies; Cancer; Development and progression; Health aspects; International economic relations; Ipilimumab; Oncology, Experimental; Pharmaceutical industry; Skin; Skin cancer; Viral antibodies
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15143564

The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been well-described in the literature. The objective of our retrospective multicenter study was to evaluate the efficacy and safety of ICI rechallenge in patients with advanced melanoma who had achieved disease control with ICI in a real-life setting. Our study, which included 85 patients, predominantly rechallenged with anti-PD1 antibodies, confirms the efficacy of ICI rechallenge, with a best overall response rate of 54% and a disease control rate of 75%. Twenty-eight adverse events (AEs) were reported in 23 patients (27%), including 18 grade 1–2 AEs and 10 grade 3–4 AEs. Therefore, ICI rechallenge should be considered as a compelling therapeutic option. Background: The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature. Patients and methods: In this retrospective multicenter national real-life study, we enrolled patients who had been rechallenged with an ICI after achieving disease control with a first course of ICI, which was subsequently interrupted. The primary objective was to evaluate tumor response, while the secondary objectives included assessing the safety profile, identifying factors associated with tumor response, and evaluating survival outcomes. Results: A total of 85 patients from 12 centers were included in the study. These patients had advanced (unresectable stage III or stage IV) melanoma that had been previously treated and controlled with a first course of ICI before undergoing rechallenge with ICI. The rechallenge treatments consisted of pembrolizumab (n = 44, 52%), nivolumab (n = 35, 41%), ipilimumab (n = 2, 2%), or ipilimumab plus nivolumab (n = 4, 5%). The best overall response rate was 54%. The best response was a complete response in 30 patients (35%), a partial response in 16 patients (19%), stable disease in 18 patients (21%) and progressive disease in 21 patients (25%). Twenty-eight adverse events (AEs) were reported in 23 patients (27%), including 18 grade 1–2 AEs in 14 patients (16%) and 10 grade 3–4 AEs in nine patients (11%). The median progression-free survival (PFS) was 21 months, and the median overall survival (OS) was not reached at the time of analysis. Patients who rec